Slide 1: Exchange filing cover letter for results presentation
May 23, 2023 The National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 (SYMBOL: THYROCARE) (SCRIP CODE 539871) Dear Sirs/Madam, Sub: Presentation- audited financial results for the
Slide 2: Thyrocare Technologies Limited Q4 and Annual Results – FY23
Thyrocare Technologies Limited Q4 and Annual Results – FY23 0
Slide 3: Safe harbour statement
Safe harbour statement Statements in this presentation describing the Company’s performance may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results may differ materially from those directly or indirectly expressed, inferred or implied. Imp
Slide 4: Agenda
Agenda 1 FY23 – A Look Back 2 Performance Highlights 3 Financial Performance 4 Going Forward Strategy 2
Slide 5: FY23 – A look back
FY23 – A look back A new Brand Identity Quality at Core • Started with T3,T4 and TSH in • Our emphasis on quality has 1996, now we offer more than 700 reached new bounds with 20 tests NABL labs including 3 COVID labs • The logo reflects our dynamism as • NABL labs 6 in FY22 to 20 labs at a bigger an
Slide 6: FY23 – Some milestones we are proud of
FY23 – Some milestones we are proud of 85% 141Mn 35% lower Quality Samples Complaints Processed in +45 pps YoY Tests per million +29% YoY (63 vs 97) NABL Labs Conducted samples 22.3Mn <24 Hrs 30,800 Operations Non-Covid samples +39% YoY TAT P90 (Vs 28 Hrs in FY22) Scans +26% YoY Go To 7400+ 4600+ 15
Slide 7: Quality at core
Quality at core 9 OUT OF 10 Doctors Recommend Thyrocare# Our Central Processing Laboratory is CAP Accredited with success score overall for Doctors trust reports to be reliable FY23 is 97.96% EQAS success score overall for FY23 Doctors satisfied with patient experience is 97.86% 5 #Source: Internati
Slide 8: FY23 – New initiatives – Expanding our offerings
FY23 – New initiatives in the year – Expanding our offerings Aarogyam - Preventive Aarogyam 24x7- Non-Fasting Jaanch - Investigative Extended our flagship preventive care series "Aarogyam" with Pro and Plus series; “Aarogyam 24x7 Non-Fasting ” packages; Launched new series of Investigation packages
Slide 9: FY23 – New initiatives – Creating awareness & trust through KOLs
FY23 – New initiatives in the year – Creating awareness & trust through KOLs 7
Slide 10: FY23 – New initiatives – Awareness through celebrities
FY23 – New initiatives in the year – Awareness through celebrities Diabetes Awareness Women’s Health Awareness Tejashri Pradhan Ganesh Chaturthi – Maharashtra Spruha Joshi Makar Sankranti – Maharashtra Dr Aditi Govitrikar Manali Manisha Dey Women’s Day Durga Pooja – Pan India – West Bengal & Orissa
Slide 11: New age tools – ThyroNxt for better client experience
New age tools – ThyroNxt for better client experience Sample On-Demand Tracking pickup Video Reporting & Guidance Analytics 9
Slide 12: Agenda
Agenda 1 FY23 – A Look Back 2 Performance Highlights 3 Financial Performance 4 Going Forward Strategy 10
Slide 13: Annual Health-Check
Annual Health-Check YoY Non-Covid Revenue YoY Non-Covid samples YoY Radiology Revenue +22% +39% +47% (22.3 Mn samples in the Year) YoY Covid Revenue YoY Pathology Revenue YoY Total Revenue* -96% -13% -11% Normalized EBIDTA Normalized EBIDTA % Profit After Tax 151 Cr 29% 66 Cr *Consolidated Revenue 1
Slide 14: Quarter Health-Check
Quarter Health-Check YoY Non-Covid Revenue YoY Total Revenue* YoY Radiology Revenue +18% +4% +53% YoY Non-Covid samples QoQ Pathology Revenue QoQ Non-Covid Revenue +20% +7% +9% (5.7 Mn samples in this Q) Normalized EBIDTA Normalized EBIDTA % Profit After Tax 41 Cr 30% 14 Cr *Consolidated Revenue 12
Slide 15: YoY Overall Pathology revenue in Q4 grew despite COVID de-growth
YoY Overall Pathology revenue in Q4 grew despite steep de-growth in COVID business Significant growth in Non COVID over last year Strong recovery of Non COVID business in FY23 Pathology Revenue (INR Cr) YoY Non Covid Growth 561.5 486.5 171.0 6.2 123.3 124.8 +22% 0.6 16.1 +18% 457.2 118.6 375.8 100.5
Slide 16: Turning a corner: Steady growth in non-COVID revenue
Turning a corner: Steady growth in non-COVID revenue over pre-COVID Levels 561.5 486.5 474.3 6.2 YoY Non-Covid Growth 171.0 400.0 370.3 0.8 151.4 0.0 FY22 vs FY19 - +2% (CAGR) 457.2 357.3 376.5 375.8 FY23 vs FY22 - +22% (Y-o-Y) 304.2 FY19 FY20 FY21 FY22 FY23 4963 2834 3121 4417 7488 # Non-Covid Acti
Slide 17: Our core business verticals continue to grow YoY
Our core business verticals continue to grow YoY – Franchise business and Partnerships main drivers of growth Non COVID Diagnostics Services Revenue (Rs Cr) Non COVID Diagnostics Services Workload (Lakhs) 39 39 72 73 37 36 68 67 65 33 33 60 62 60 30 28 18 17 17 38 38 38 16 35 31 14 28 25 20 8 8 5 Q1
Slide 18: Agenda
Agenda 1 FY23 – A Look Back 2 Performance Highlights 3 Financial Performance 4 Going Forward Strategy 16
Slide 19: Income Statement – Pathology
Income Statement – Pathology Quarter Annual Pathology revenue decreased INR crore Q4 22 Q4 23 YoY FY 22 FY 23 YoY 13% Y-o-Y in FY23 due to steep Revenue from operations 123.33 124.82 1% 561.53 486.46 -13% degrowth in COVID revenue (40.63) (39.64) -2% (165.23) (156.37) -5% (171 Cr in FY22 vs 6 Cr in
Slide 20: Income Statement – Radiology
Income Statement – Radiology Quarter Annual Revenue from imaging INR crore Q4 22 Q4 23 YoY FY 22 FY 23 YoY services grew 47% Y-o-Y in Revenue from operations 7.22 11.06 53% 27.35 40.21 47% FY23 through opening of two Cost of materials consumed/ sold (1.26) (2.11) 67% (4.46) (6.86) 54% new centers (S
Slide 21: Income Statement – Consolidated
Income Statement – Consolidated Quarter Annual Diagnostics revenue decreased INR crore Q4 22 Q4 23 YoY FY 22 FY 23 YoY 11% Y-o-Y in FY23 due to steep Revenue from operations 130.56 135.88 4% 588.86 526.67 -11% degrowth in COVID revenue (171 Cost of materials consumed/ sold (41.89) (41.75) 0% (169.69
Slide 22: Agenda
Agenda 1 FY23 – A Look Back 2 Performance Highlights 3 Financial Performance 4 Going Forward Strategy 20
Slide 23: Vision & Mission
Vision & Mission Vision To be the best provider of diagnostic solutions to all stakeholders in healthcare - be it a single doctor, polyclinics, a health check up patient, a diagnostic lab, a nursing home, a large hospital, medical and health tech platforms or the Government Mission To ensure everyon
Slide 24: Our Strategy remains to be a B2B service provider
Our Strategy remains to be a B2B service provider with an affordable value driven model based on scale efficiencies 61% 33% Franchise Partnerships + B2G -Mom & Pop collection centers -Online diagnostics aggregators -31 Labs (including 3 COVID labs) -Local labs -Healthcare platforms -Lab within 200Km
Slide 25: Going forward - Key Pillars of growth
Going forward - Key Pillars of growth Public & Private International Franchise Partnerships Expansion • Going deeper into India with • Focus on TB and Infectious • Exploring to take our B2B model focused test menu Disease along with large to emerging markets to deliver screening programs run by affo
Slide 26: Leadership Team
Leadership Team Piyush Singh Head - Partnerships & D2C Sachin Salvi Amit Bhola CFO & Nueclear Business Head Head - Franchise Business Rahul Guha MD & CEO Dr Chaitali Nikam Head - TB & Infectious Diseases Harinder Gill Dr Preet Kaur Aditya Shinde Krishnakumar S Head - Network Operations & CRM Head -
Slide 27: Thank You
Thank You Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development,